Skip to content
Original Research
J Clin Psychiatry
March 2026
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia
Full Article
Read the complete peer-reviewed article in J Clin Psychiatry.
Clinical Summary
Negative symptoms remain one of the hardest-to-treat drivers of poor functioning in schizophrenia, and gains in motivation, interest, and expressive functioning often lag behind improvement in acute psychosis. This analysis asks a practical question for long-term treatment: whether improvement in negative symptoms with olanzapine/samidorphan persists and deepens over 56 weeks, including in patients with prominent or predominantly negative symptoms at baseline.
FAQ
Did olanzapine/samidorphan improve negative symptoms of schizophrenia over 56 weeks?
10 questions
Key Takeaways
Negative symptom improvement accrued beyond the acute phase: LS mean changes in PANSS Negative Subscale and Marder Negative Factor scores were −4.1 (0.24) and −4.5 (0.24) at week 4, improving further to −7.6 (0.35) and −8.2 (0.35) at week 56.
6 takeaways
Clinical Guide
How can clinicians identify patients with schizophrenia who have prominent or predominantly negative symptoms using the criteria applied in this analysis?
5 steps
Clinical Guide
How should clinicians track negative symptom change over time in patients with schizophrenia treated with olanzapine/samidorphan based on this 56-week analysis?
7 steps
